Mandate

Vinge has advised CELLINK in connection with directed issues of SEK 3 billion

Vinge has advised CELLINK AB (publ) in connection with a directed issue of covertibles of SEK 1.5 billion and a directed issue of B-shares of SEK 1.5 billion, in total SEK 3 billion.

The convertibles and the shares have been offered by way of an accelerated bookbuilding process arranged by Citigroup Global Markets, J.P. Morgan and Carnegie Investment Bank. The convertibles and shares were subscribed for by Swedish and international institutional investors.

Vinge’s team has consisted of Anders Strid, Edin Agic, Hampus Olsson, Linus Adolfsson and Maria Schultzberg (tax). Sullivan & Cromwell has advised Cellink in relation to English and US laws.

Related

Vinge has advised Verisure in connection with its IPO on Nasdaq Stockholm

Vinge has advised Verisure plc (“Verisure”) in connection with its IPO on Nasdaq Stockholm. Following the publication of the prospectus on 29 September 2025, trading in Verisure’s shares commenced today, 8 October 2025.
October 08, 2025

Vinge has acted for Advania on the acquisition of smartvokat

smartvokat GmbH, a German-based consultancy specialising in digital transformation within the legal, risk, and compliance domains, will become part of Advania’s business unit Transformation & Automation.
October 08, 2025

Vinge has advised Egetis Therapeutics in connection with a directed share issue

Vinge has advised Egetis Therapeutics AB (publ) (“Egetis Therapeutics”), listed on Nasdaq Stockholm, in connection with a directed share issue whereby Egetis Therapeutics raised proceeds of approximately SEK 183 million before transaction costs.
October 06, 2025